Brain Derived Neurotrophic Factor and cognitive markers in subjects with Alzheimer’s disease
Keywords:
Brain derived neurotrophic factor, episodic memory, executive functions, mild cognitive impairment, Alzheimer’s disease.Abstract
Introduction: The brain derived neurotrophic factor is a neurotrophinmodulator of cognitive processes. Current studies in Alzheimer’s disease
patients show alterations in biomarkers at outlying levels.
Objective: To analyze the association between the serum brain-derived neurotrophic factor levels and the cognitive markers in Alzheimer’s disease subjects.
Material and Methods: A correlational transversal study was conducted in subjects aged 64 years, distributed into three groups: group 1ː16 controls, group 2ː27 with mild cognitive impairment, and group 3ː21 with Alzheimer’s disease. A neuropsychological test battery, and the immunoenzymatic method (ELISA), Promega Emax Kit were applied to determine the serum brain-derived neurotrophic factor levels. The statistical analysis of data was performed using the one-way ANOVA test, the post-hoc Dunnett´s test and the Pearson’s correlation coefficient (p<0.05).
Results: The serum brain-derived neurotrophic factor levels were lower in the groups with Alzheimer’s disease and mild cognitive impairment. The factor levels were correlated with the episodic memory, the executive functions, and the global cognitive function in Alzheimer’s disease patients. In the mild cognitive impairment group, the serum brain-derived neurotrophic factor was only associated with the executive functionl.
Conclusions: The serum brain-derived neurotrophic factor levels diminish in association with cognitive impairment in Alzheimer’s disease. Furthermore, this factor linked to the executive domain dysfunction is suggested as a potential biomarker of neuroplasticity in the preclinical detection of this pathology.
Downloads
References
1. Alzheimer A, Schnitzlein H, Murtagh F. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat. 1995;8(6):429-31. ISSN 0897-3806. doi: 10.1002/ca.980080612
2. Villain N. Alzheimer's Disease Including Focal Presentations Semin Neurol. 2019 Apr;39(2):213-26. PMID: 30925614. Epub 2019 Mar 29. doi: 10.1055/s-0039-1681041
3. World Health Organization et al. Risk reduction of cognitive decline and dementia: WHO guidelines; 2019. Geneva. Licence: CC BY-NC-SA 3.0 IGO. ISBN 978-92-4-155054-3. Disponible en: http://apps.who.int/iris
4. V Ana, G Estela, Ll Juan, C Pastor, B Rodolfo, Z Tania. Percepción de las demencias y la intersectorialidad en el contexto del Policlínico Docente Playa. Rev Cubana Salud Pública. 2019 [acceso: 16/1/2021]; 45(1):1128. ISSN 1561-3127. Disponible en: https://www.scielosp.org/article/rcsp/2019.v45n1/e1128/#;45(1):1128
5. Prendes-Rivero N, Verde C, López-González B, De los Ángeles M y Mesa NB. Efectos neuroplásticos de la depresión en la enfermedad de Alzheimer. Rev Cubana Hospital Psiquiátrico de la Habana. 2022. ISSN: 0138-7103
6. Seo E, Lim H, Yoon H-J, Choi K, Lee J and Park J. Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer’s continuum. Alz Res Therapy, 2021, 13:167. Disponible en: https://doi.org/10.1186/s13195-021-00909-1
7. García A, Stögmann E, Lehrner J. Predicción neuropsicológica de la demencia utilizando la batería de pruebas neuropsicológicas de Viena: un estudio retrospectivo. Science Direct Elservier, Brain disorders. 2022, 5, 100028. Disponible en: https://doi.org/10.1016/j.dscb.2021.100028
8. Hameed S, Fuh J, Senanarong V, Ebenezer E, Looi I, Dominguez J et al. Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease. J. Alzheimers Dis. Rep. 2020, 4, 21–37. Disponible en: doi: 10.3233/ADR-190143
9. Dubois B. The Emergence of a New Conceptual Framework for Alzheimer’s Disease. Journal of Alzheimer's Disease. 2018;62(3):1059-66. doi: 10.3233/JAD-170536
10. Mori Y, Tsuji M, Oguchi T, Kasuga K, Kimura A, Futamura A et al. Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. Front Neurol. 2021;12: 653267. doi: 10.3389/fneur.2021.653267
11. Jack C, Bennett D, Blennow K, Carrillo M, Dunn B, Haeberlein B et al. NIAAA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 2018;14(4):535-62. doi: 10.1016/j.jalz.2018.02.018
12. Azmán K, Zakaria R. Avances recientes sobre el papel del factor neurotrófico derivado del cerebro (BDNF) en las enfermedades neurodegenerativas. En J. Mol. Ciencia, 2022, 23, 6827. Disponible en: https://doi.org/10.3390/ijms23126827
13. Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK. The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease. Life Sci. 2020; 257:118020. doi: 10.1016/j.lfs.2020.118020
14. Hashem A, Ashraf G, Maqbool T. Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. Front Aging Neurosci. 2022 Sep 14:977411. Disponible en: https://www.frontiersin.org/articles/10.3389/fnagi.2022.977411
15. Ng TK, Ho R, Tam W, Kua E, Ho R. Decreased serum brain derived neurotrophic factor levels in patients with Alzheimer's disease (AD): a systematic review and meta-analysis. Int J Mol Sci 2019; 20:257. PMID: 30634650. IDPM: PMC6358753. doi: 10.3390/ijms20020257
16. Mizoguchi Y, Yao H, Imamura Y et al. Los niveles más bajos del factor neurotrófico derivado del cerebro están asociados con el deterioro de la memoria relacionado con la edad en adultos mayores que viven en la comunidad: el estudio Sefuri. Informe científico 10, 16442 (2020). https://doi.org/10.1038/s41598-020-73576-1
17. Angelucci F, di Iulio F, Ciaramella A, Salani F, Colantoni L et al. Alzheimer's disease (AD) and Mild Cognitive Impairment patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7(1):15-20. Disponible en: http://refhub.elsevier.com/S0278-5846(13)00270-4/rf0005
18. Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Translational Neurodegeneration, 2022, 11:4. Disponible en: https://doi.org/10.1186/s40035-022-00279-0
19. Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6
20. Schmidt M. Rey Auditory-Verbal Learning Test. Los Angeles: Western Psychological Services. 1996. doi: 10.1007/978-0-387-79948-3_1153
21. Visser P, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006 Oct 10;67(7):1201-7. doi: 10.1212/01.wnl.0000238517.59286.c5. PMID: 17030753.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed Washington DC: American Psychiatric Association; 2013. Disponible en: http://repository.poltekkeskaltim.ac.id/657/1/pdf
23. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Asamblea General, Fortaleza, Brasil. 2013;64. Disponible en:
http://www.uchile.cl/documentos/declaracion-de-helsinki-2013_76961_14_4053.pdf
24. Gao X, Chen Q, Yao H, Tan J, Liu Z, Zhou Y et al. Epigenetics in Alzheimer’s Disease. Front Aging Neurosci. 2022; 14: 911635. PMCID: PMC9260511. PMID: 35813941. doi: 10.3389/fnagi.2022.911635
25. Weinstein G, Choi S, Preis S, Chen T, Vorgas D, Au R et al. Serum brain-derived neurotrophic factor and the risk for dementia: The Framingham Heart Study. JAMA Neurol. 2014;71:55-61. doi:10.1001/jamaneurol.2013.4781
26. Hiroyuki S, Takeh, DaisukeY, KotaT,Yuya K, Sangyoon L et al. A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly Frontiers org, anging and neuroscience Neuroscience. 2015. Disponible en: http://wwwfrontiersinorg/Aging
27. Diniz B, Reynolds C, Begley A, Dew M, Anderson S, Lotrich F et al. Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study. J. Psychiatr Res 2014;49:96-101. Disponible en: https://doi.org/10.1016/j.jpsychires.2013.11.004
28. Laske C, Hoffmann N, Stransky E, Straten G et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum, 2011;14: 399-404. doi:10.1017/S1461145710001008
29. N Jasmine,M Eleanor, HTamara, S Suzanne, R Caterina, Y Kristine. The Associations between Serum Brain-Derived Neurotrophic Factor Potential Confounders and Cognitive Decline: A Longitudinal Study. Renping Zhou, Rutgers University, United States of America, 2014, 9, 3. Disponible en:https://doi.org/10.1371/journal.pone.0091339
Download PDF
